表紙
市場調查報告書

個人利用血糖自我測量儀的全球市場 - 成長,趨勢,預測(2019年∼2024年)

Personal use Self monitoring Blood Glucose Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 808271
出版日期 內容資訊 英文 100 Pages
商品交期: 2-3個工作天內
價格
個人利用血糖自我測量儀的全球市場 - 成長,趨勢,預測(2019年∼2024年) Personal use Self monitoring Blood Glucose Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 100 Pages
簡介

由於糖尿病患者對個人利用的血糖自我測量儀的認識度上升,近幾年持續成長著。由於血糖儀的技術創新和利用性的好處,糖尿病前期患者及糖尿病患者注意力集中在血糖水平的測量和監測上。

本報告提供全球個人利用血糖自我測量儀市場調查,市場概要,各醫藥品類型、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查結果
  • 前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各利用方法
  • 各零件
    • 血糖儀
    • 測試紙
    • 採血針
  • 各地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲

第6章 市場區隔

  • 第一型糖尿病的患者數
  • 第二型糖尿病的患者數

第7章 競爭情形

  • 企業簡介
    • Abbott Diabetes Care
    • Roche
    • Johnson & Johnson
    • Arkray
    • Ascensia Diabetes Care
    • Agamatrix Inc.
    • Bionime Corporation
    • Acon
    • Trivida
    • Rossmax

第8章 市場機會與未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 66053

Market Overview

The personal-use self-monitoring blood glucose (SMBG) market has grown in recent years, due to an increased awareness among diabetes patients. New technological innovations in glucometers and their ease of usage, have made diabetes and pre-diabetes patients more conscientious in monitoring and controlling their blood glucose levels.

Currently, the home user market holds the highest market share and is expected to increase. As a result of this, the demand for home usage of self-monitoring blood glucose devices is not only high among diabetes patients, but also among other people who want to know their health situation regularly.

One of the fastest-growing chronic diseases in the world is diabetes. Diabetes is a disease that occurs when the glucose levels of the body increase to more than the normal level, and the body is unable to produce insulin. Glucometers are used to monitor glucose levels. The type 1 diabetes population around the world is rising, while witnessing a CAGR of 2.13%. As the diabetic population increases, the self-monitoring blood glucose devices market is also bound to increase.

Other factors, such as technological innovations, the convenience of conventional glucose monitoring over regular monitoring, and early detection of hypo- and hyperglycemic diabetes are the primary drivers for market growth.

Scope of the Report

The market is segmented by component (glucometer device, blood glucose test strips, lancets), and geography.

Key Market Trends - Blood Glucose Test Strips Hold the Highest Market Share

Blood glucose test strips have the highest market share, with 77%, in the global personal usage market of self-monitoring blood glucose (SMBG) devices. As the blood glucose test strips are only for one-time use, the expenditure spent on test strips is high because of the need for their continuous replacement.

The glucometer is considered to be a one-time purchase. Test strips, on the other hand, are supposed to be a continuous investment, as a test strip needs to be disposed of after one use. Thus, this presents a considerable cost impact to the consumers.

Overall, the global demand for blood glucose test strips is projected to witness significant growth over the forecast period. The growth of the market studied is expected to be spurred by the rising global diabetic population.

The growth in market volumes and share of the test strip segment is expected to be better than that of glucometers, because of the difference in use-case frequency. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost, during the same time frame, the corresponding use of multiple (in the range of thousands) test strips may occur, causing a recurrent cost impact.

North America has the Highest Market Share, with a 21.63% CAGR

The North America test strips market has the highest market share, with a revenue of USD 2 billion, followed by Europe and Asia-Pacific.

The United States alone has around 80% share in the North America blood glucose test strips market.

The price policies and favorable reimbursement policies in North America are driving the growth of the North America personal-use glucometer device market.

Competitive Landscape

The global personal-use glucometer market is highly consolidated, with a few major manufacturers having their presence in major regions of the global market, while the remaining manufacturers are limited to other local or region-specific manufacturers.

The innovations in self-monitoring blood glucose devices are increasing and are under development.

ColorSure Dynamic Range Indicator (ColorSure® PLUS) is an expansion of ColorSure® technology from the OneTouch brand. ColorSure PLUS technology is designed to help patients understand when glucose results are nearing highs or lows.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Usage
    • 5.1.1 Personal-use Self-monitoring Blood Glucose Devices (Value and Volume, 2012 - 2024)
  • 5.2 By Component
    • 5.2.1 Glucometer Devices
    • 5.2.2 Test Strips
    • 5.2.3 Lancets
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States (Value and Volume, 2012 - 2024)
      • 5.3.1.1.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.1.2 Canada (Value and Volume, 2012 - 2024)
      • 5.3.1.2.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.1.3 Rest of North America (Value and Volume, 2012 - 2024)
      • 5.3.1.3.1 By Device (Glucometer Device, Test Strips, Lancets)
    • 5.3.2 Europe
      • 5.3.2.1 France (Value and Volume, 2012 - 2024)
      • 5.3.2.1.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.2.2 Germany (Value and Volume, 2012 - 2024)
      • 5.3.2.2.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.2.3 Italy (Value and Volume, 2012 - 2024)
      • 5.3.2.3.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.2.4 Spain (Value and Volume, 2012 - 2024)
      • 5.3.2.4.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.2.5 United Kingdom (Value and Volume, 2012 - 2024)
      • 5.3.2.5.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.2.6 Russia (Value and Volume, 2012 - 2024)
      • 5.3.2.6.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.2.7 Rest of Europe (Value and Volume, 2012 - 2024)
      • 5.3.2.7.1 By Device (Glucometer Device, Test Strips, Lancets)
    • 5.3.3 Latin America
      • 5.3.3.1 Mexico (Value and Volume, 2012 - 2024)
      • 5.3.3.1.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.3.2 Brazil (Value and Volume, 2012 - 2024)
      • 5.3.3.2.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.3.3 Rest of Latin America (Value and Volume, 2012 - 2024)
      • 5.3.3.3.1 By Device (Glucometer Device, Test Strips, Lancets)
    • 5.3.4 Asia-Pacific
      • 5.3.4.1 Japan (Value and Volume, 2012 - 2024)
      • 5.3.4.1.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.4.2 South Korea (Value and Volume, 2012 - 2024)
      • 5.3.4.2.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.4.3 China (Value and Volume, 2012 - 2024)
      • 5.3.4.3.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.4.3.2 By End User (Hospital and Home)
      • 5.3.4.4 India (Value and Volume, 2012 - 2024)
      • 5.3.4.4.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.4.4.2 By End User (Hospital and Home)
      • 5.3.4.5 Australia (Value and Volume, 2012 - 2024)
      • 5.3.4.5.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.4.6 Vietnam (Value and Volume, 2012 - 2024)
      • 5.3.4.6.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.4.7 Malaysia (Value and Volume, 2012 - 2024)
      • 5.3.4.7.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.4.8 Indonesia (Value and Volume, 2012 - 2024)
      • 5.3.4.8.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.4.9 Philippines (Value and Volume, 2012 - 2024)
      • 5.3.4.9.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.4.10 Thailand (Value and Volume, 2012 - 2024)
      • 5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 - 2024)
      • 5.3.4.11.1 By Device (Glucometer Device, Test Strips, Lancets)
    • 5.3.5 Middle East & Africa
      • 5.3.5.1 Saudi Arabia (Value and Volume, 2012 - 2024)
      • 5.3.5.1.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.5.1.2 By End User (Hospital and Home)
      • 5.3.5.2 Iran (Value and Volume, 2012 - 2024)
      • 5.3.5.2.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.5.3 Egypt (Value and Volume, 2012 - 2024)
      • 5.3.5.3.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.5.4 Oman (Value and Volume, 2012 - 2024)
      • 5.3.5.4.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.5.5 South Africa (Value and Volume, 2012 - 2024)
      • 5.3.5.5.1 By Device (Glucometer Device, Test Strips, Lancets)
      • 5.3.5.6 Rest of Middle & Africa (Value and Volume, 2012 - 2024)
      • 5.3.5.6.1 By Device (Glucometer Device, Test Strips, Lancets)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2024)
  • 6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Roche
    • 7.1.3 Johnson & Johnson
    • 7.1.4 Arkray
    • 7.1.5 Ascensia Diabetes Care
    • 7.1.6 Agamatrix Inc.
    • 7.1.7 Bionime Corporation
    • 7.1.8 Acon
    • 7.1.9 Trivida
    • 7.1.10 Rossmax

8 MARKET OPPORTUNITIES AND FUTURE TRENDS